Nakas Apostolos, Trousse Delphine Sophie, Martin-Ucar Antonio E, Waller David A
Department of Thoracic Surgery, Glenfield Hospital, Groby Road, Leicester LE3 9QA, United Kingdom.
Eur J Cardiothorac Surg. 2008 Oct;34(4):886-91. doi: 10.1016/j.ejcts.2008.06.010. Epub 2008 Jul 24.
To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP).
We reviewed 102 consecutive patients (93 male; 9 female, mean age 63 years) who were not suitable for EPP because of either advanced tumour stage or suboptimal fitness. Patients underwent either a non-radical tumour decortication to obtain lung expansion (group NR) or latterly a radical pleurectomy/decortication to obtain macroscopic tumour clearance (group R). We analysed the comparative perioperative courses and long-term survival.
The two groups were similar for age and gender distribution but epithelioid type was more predominant in group R: 78% compared to 55% epithelioid in group NR. Thirty-day mortality was similar (5.9% in group R and 9.8% in the group NR, p=0.36) but 90-day mortality was significantly higher in the group NR (29.4% vs 9.8% in group R, p=0.012). More patients in group R received adjuvant chemotherapy (65% vs 28%, p=0.000) and radiotherapy (65% vs 26%, p=0.000). Median survival for all cell types was significantly higher in group R (15.3 months vs 7.1 months, p<0.000). Group R survival rates at 1, 2, 3 and 4 years were 53, 41, 25 and 13%, respectively while for group NR they were 32, 9.6, 2 and 0%, respectively. For epithelioid cell type there was still a significant median survival advantage in group R (25.4 months vs 10.2 months, p<0.000), but there was no difference for sarcomatoid (9.3 months vs 3.2 months, p=0.16) or biphasic cell types (9.4 months vs 7 months, p=0.38).
If a patient with epithelioid MPM is fit enough to tolerate a thoracotomy then macroscopic clearance of the tumour is the preferred option as part of a multimodality regime including chemotherapy.
确定不适于接受胸膜外全肺切除术(EPP)的恶性胸膜间皮瘤患者的最佳减瘤手术方法。
我们回顾性分析了102例连续患者(93例男性,9例女性,平均年龄63岁),这些患者因肿瘤分期较晚或身体状况欠佳而不适于接受EPP。患者接受了非根治性肿瘤剥脱术以实现肺扩张(NR组),或接受了根治性胸膜切除术/剥脱术以实现肉眼可见的肿瘤清除(R组)。我们分析了围手术期过程和长期生存率的比较情况。
两组在年龄和性别分布上相似,但R组上皮样型更为常见:R组为78%,而NR组为55%。30天死亡率相似(R组为5.9%,NR组为9.8%,p = 0.36),但NR组90天死亡率显著更高(29.4%对R组的9.8%,p = 0.012)。R组更多患者接受了辅助化疗(65%对28%,p = 0.000)和放疗(65%对26%,p = 0.000)。所有细胞类型的中位生存期在R组显著更高(15.3个月对7.1个月,p < 0.000)。R组1、2、3和4年的生存率分别为53%、41%、25%和13%,而NR组分别为32%、9.6%、2%和0%。对于上皮样细胞类型,R组仍有显著的中位生存期优势(25.4个月对10.2个月,p < 0.000),但肉瘤样细胞类型(9.3个月对3.2个月,p = 0.16)或双向细胞类型(9.4个月对7个月,p = 0.38)无差异。
如果上皮样型恶性胸膜间皮瘤患者身体状况足以耐受开胸手术,那么作为包括化疗在内的多模式治疗方案的一部分,肉眼可见的肿瘤清除是首选方案。